Related references
Note: Only part of the references are listed.The Block-and-Lock Strategy for Human Immunodeficiency Virus Cure: Lessons Learned from Didehydro-Cortistatin A
Chuan Li et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank
Maarten H. Geurts et al.
CELL STEM CELL (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Block-And-Lock Strategies to Cure HIV Infection
Gerlinde Vansant et al.
VIRUSES-BASEL (2020)
Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
Yubin Liu et al.
EMERGING MICROBES & INFECTIONS (2020)
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
Qian Wang et al.
FRONTIERS OF MEDICINE (2020)
Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure
Luisa Mori et al.
VIRUSES-BASEL (2020)
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report
Ravindra Kumar Gupta et al.
LANCET HIV (2020)
Block-And-Lock: New Horizons for a Cure for HIV-1
Ines Moranguinho et al.
VIRUSES-BASEL (2020)
Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+Hematopoietic Stem and Progenitor Cells
Haydar Frangoul et al.
BLOOD (2020)
CRISPR therapy towards an HIV cure
Elena Herrera-Carrillo et al.
BRIEFINGS IN FUNCTIONAL GENOMICS (2020)
Early antiretroviral treatment of infants to attain HIV remission
Louise Kuhn et al.
ECLINICALMEDICINE (2020)
From APOBEC to ZAP: Diverse mechanisms used by cellular restriction factors to inhibit virus infections
Mahesh Chemudupati et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation
Avy Violari et al.
NATURE COMMUNICATIONS (2019)
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Qiaoqiao Xiao et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation
Sonia Mediouni et al.
FASEB JOURNAL (2019)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
HIV shock and kill therapy: In need of revision
Erik Abner et al.
ANTIVIRAL RESEARCH (2019)
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Geetha Mylvaganam et al.
FRONTIERS IN IMMUNOLOGY (2019)
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
Eytan Herzig et al.
CELL (2019)
T-cell exhaustion in HIV infection
Craig Fenwick et al.
IMMUNOLOGICAL REVIEWS (2019)
Getting the Kill into Shock and Kill: Strategies to Eliminate Latent HIV
Youry Kim et al.
CELL HOST & MICROBE (2018)
CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Miliotou N. Androulla et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2018)
New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment
Lucio Gama et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Nadia Madrid-Elena et al.
JOURNAL OF VIROLOGY (2018)
A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other Shock Drugs
Erik Abner et al.
JOURNAL OF VIROLOGY (2018)
Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children
Louise Kuhn et al.
PLOS ONE (2018)
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
Matthew D. Marsden et al.
VIROLOGY (2018)
CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy
Shuliang Chen et al.
VIRUSES-BASEL (2018)
InducingCCR5Δ32/Δ32 Homozygotes in the Human Jurkat CD4+Cell Line and Primary CD4+Cells by CRISPR-Cas9 Genome-Editing Technology
Chunxia Qi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Follicular CD4 T Helper Cells As a Major HIV Reservoir Compartment: A Molecular Perspective
Malika Aid et al.
FRONTIERS IN IMMUNOLOGY (2018)
Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing
Chengzu Long et al.
SCIENCE ADVANCES (2018)
Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments
Michelle L. Kimberland et al.
JOURNAL OF BIOTECHNOLOGY (2018)
The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies
Golnaz Namazi et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza et al.
NATURE (2018)
RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency
Catalina Mendez et al.
RETROVIROLOGY (2018)
Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
George B. Kyei et al.
MBIO (2018)
Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV
M. A. Rochat et al.
JOURNAL OF VIROLOGY (2017)
TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus
Bingjie Shi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2017)
Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys
Boris Julg et al.
JOURNAL OF VIROLOGY (2017)
The therapeutic landscape of HIV-1 via genome editing
Alexander Kwarteng et al.
AIDS RESEARCH AND THERAPY (2017)
Non-Homologous End Joining and Homology Directed DNA Repair Frequency of Double-Stranded Breaks Introduced by Genome Editing Reagents
Michail Zaboikin et al.
PLOS ONE (2017)
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
Brice J. Albert et al.
SCIENTIFIC REPORTS (2017)
Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription
Tsuyoshi Hayashi et al.
ANTIVIRAL RESEARCH (2017)
Novel AIDS therapies based on gene editing
Kamel Khalili et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Didehydro-Cortistatin A: a new player in HIV-therapy?
Guillaume Mousseau et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
The clinical applications of genome editing in HIV
Cathy X. Wang et al.
BLOOD (2016)
CRISPR-mediated Activation of Latent HIV-1 Expression
Prajit Limsirichai et al.
MOLECULAR THERAPY (2016)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid et al.
NATURE (2016)
PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals
Riddhima Banga et al.
NATURE MEDICINE (2016)
Shock and kill with caution
Robert C. Gallo
SCIENCE (2016)
Which therapeutic strategy will achieve a cure for HIV-1?
Anthony R. Cillo et al.
CURRENT OPINION IN VIROLOGY (2016)
Specific Destruction of HIV Proviral p17 Gene in T Lymphoid Cells Achieved by the Genome Editing Technology
Tsunao Kishida et al.
FRONTIERS IN MICROBIOLOGY (2016)
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Hilde Almasbak et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report
Pierre Frange et al.
LANCET HIV (2016)
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens
Sam Afkhami et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
Heloise M. Delagreverie et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems
Julia K. Bialek et al.
PLOS ONE (2016)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells
Manoj K. Tripathy et al.
JOURNAL OF VIROLOGY (2015)
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey et al.
NATURE (2015)
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Kai Deng et al.
NATURE (2015)
HIV reservoirs as obstacles and opportunities for an HIV cure
Tae-Wook Chun et al.
NATURE IMMUNOLOGY (2015)
B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers
Yoshinori Fukazawa et al.
NATURE MEDICINE (2015)
Damaging the Integrated HIV Proviral DNA with TALENs
Christy L. Strong et al.
PLOS ONE (2015)
Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators
Hal P. Bogerd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency
Guillaume Mousseau et al.
MBIO (2015)
Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection
Panpan Hou et al.
SCIENTIFIC REPORTS (2015)
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs
Yonggang Zhang et al.
SCIENTIFIC REPORTS (2015)
CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus
HyunJun Kang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing
Chantelle Ahlenstiel et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells
Gert U. van Zyl et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling
Guochun Jiang et al.
AIDS (2014)
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
Ariel Halper-Stromberg et al.
CELL (2014)
Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
William Wold et al.
CURRENT GENE THERAPY (2014)
Emerging strategies to deplete the HIV reservoir
Nancie M. Archin et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1
Roger Badia et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
HIV Type 1 (HIV-1) Proviral Reservoirs Decay Continuously Under Sustained Virologic Control in HIV-1-Infected Children Who Received Early Treatment
Katherine Luzuriaga et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial
Richard B. Pollard et al.
LANCET INFECTIOUS DISEASES (2014)
HIV-1 persistence in CD4+ T cells with stem cell like properties
Maria J. Buzon et al.
NATURE MEDICINE (2014)
Zinc-finger nucleases make the cut in HIV
Brian Owens
NATURE REVIEWS DRUG DISCOVERY (2014)
More on Shift of HIV Tropism in Stem-Cell Transplantation with CCR5 Delta32/Delta32 Mutation
Gero Huetter
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Shift of HIV Tropism in Stem-Cell Transplantation with CCR5 Delta32 Mutation
Lambros Kordelas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection
Weiming Wang et al.
PLOS ONE (2014)
Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection
Lin Ye et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
Zhitao Wan et al.
RETROVIROLOGY (2014)
Immunologic strategies for HIV-1 remission and eradication
Dan H. Barouch et al.
SCIENCE (2014)
HIV cure research: Advances and prospects
Caroline P. Passaes et al.
VIROLOGY (2014)
HIV-1 Latency: An Update of Molecular Mechanisms and Therapeutic Strategies
Angela Battistini et al.
VIRUSES-BASEL (2014)
Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
Ulrike Mock et al.
SCIENTIFIC REPORTS (2014)
HIV-1 DNA predicts disease progression and post-treatment virological control.
James P. Williams et al.
ELIFE (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells
Fiona Wightman et al.
AIDS (2013)
Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases
Lijing Li et al.
MOLECULAR THERAPY (2013)
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Masashi Shingai et al.
NATURE (2013)
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
Dan H. Barouch et al.
NATURE (2013)
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Seung Woo Cho et al.
NATURE BIOTECHNOLOGY (2013)
Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy
Wolfgang Stoehr et al.
PLOS ONE (2013)
Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues
Anthony P. West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication
Felipe Garcia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Targeted gene disruption to cure HIV
Daniel Stone et al.
CURRENT OPINION IN HIV AND AIDS (2013)
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Hirotaka Ebina et al.
SCIENTIFIC REPORTS (2013)
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
Asier Saez-Cirion et al.
PLOS PATHOGENS (2013)
An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription
Guillaume Mousseau et al.
CELL HOST & MICROBE (2012)
Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme
Jianbin Wang et al.
GENOME RESEARCH (2012)
Generation of CD34+ Cells from CCR5-Disrupted Human Embryonic and Induced Pluripotent Stem Cells
Yongchao Yao et al.
HUMAN GENE THERAPY (2012)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Combination of Biological Screening in a Cellular Model of Viral Latency and Virtual Screening Identifies Novel Compounds That Reactivate HIV-1
Edurne Gallastegui et al.
JOURNAL OF VIROLOGY (2012)
Zinc-finger Nuclease Editing of Human cxcr4 Promotes HIV-1 CD4+ T Cell Resistance and Enrichment
Jinyun Yuan et al.
MOLECULAR THERAPY (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Florian Klein et al.
NATURE (2012)
Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses
Dennis R. Burton et al.
SCIENCE (2012)
Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency
Shailesh K. Choudhary et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Genome Engineering With Zinc-Finger Nucleases
Dana Carroll
GENETICS (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir
Shay Matalon et al.
MOLECULAR MEDICINE (2011)
XPB, a subunit of TFIIH, is a target of the natural product triptolide
Denis V. Titov et al.
NATURE CHEMICAL BIOLOGY (2011)
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control
Adam R. Hersperger et al.
CURRENT OPINION IN HIV AND AIDS (2011)
Histone deacetylase inhibitors and HIV latency
David M. Margolis
CURRENT OPINION IN HIV AND AIDS (2011)
Engineering HIV-Resistant Human CD4+T Cells with CXCR4-Specific Zinc-Finger Nucleases
Craig B. Wilen et al.
PLOS PATHOGENS (2011)
Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Moises Perez et al.
CURRENT HIV RESEARCH (2010)
TAL effectors: finding plant genes for disease and defense
Adam J. Bogdanove et al.
CURRENT OPINION IN PLANT BIOLOGY (2010)
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
Nathalia Holt et al.
NATURE BIOTECHNOLOGY (2010)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Nicolas Chomont et al.
NATURE MEDICINE (2009)
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Jens Boch et al.
SCIENCE (2009)
A Simple Cipher Governs DNA Recognition by TAL Effectors
Matthew J. Moscou et al.
SCIENCE (2009)
CpG Methylation Controls Reactivation of HIV from Latency
Jana Blazkova et al.
PLOS PATHOGENS (2009)
Epigenetic Regulation of HIV-1 Latency by Cytosine Methylation
Steven E. Kauder et al.
PLOS PATHOGENS (2009)
HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors
Veronique Avettand-Fenoel et al.
AIDS (2008)
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)
Brigitte Autran et al.
AIDS (2008)
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
Peter Gimsing et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region
Kazuo Suzuki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Elena E. Perez et al.
NATURE BIOTECHNOLOGY (2008)
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue
Elizabeth Connick et al.
JOURNAL OF IMMUNOLOGY (2007)
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
Luis H. Camacho et al.
INVESTIGATIONAL NEW DRUGS (2007)
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Constantinos Petrovas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Lydie Trautmann et al.
NATURE MEDICINE (2006)
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Michael R. Betts et al.
BLOOD (2006)
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals
Y Lévy et al.
AIDS (2006)
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
S Kinloch-de Loes et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
G Lehrman et al.
LANCET (2005)
Therapeutic Vaccines for chronic infections
B Autran et al.
SCIENCE (2004)
CD4 cell response to 3 doses of subcutaneous interleukin 2: Meta-analysis of 3 Vanguard studies
RC Arduino et al.
CLINICAL INFECTIOUS DISEASES (2004)
Immunopathogenesis and immunotherapy in AIDS virus infections
NL Letvin et al.
NATURE MEDICINE (2003)
Share Paper
